Strong Q2 Performance: Edwards Lifesciences reported second quarter sales of $1.53 billion, a 10.6% increase year-over-year, exceeding expectations. This sales growth was primarily driven by TAVR (transcatheter aortic valve replacement) sales of $1.1 billion, which rose 7.8%, and a remarkable 57% growth in TMTT (transcatheter mitral and tricuspid therapies) sales of $133 million.

Increased Guidance for 2025: Based on the strong first half performance and positive growth trends, the company raised its full-year sales growth guidance to 9% to 10%, with total sales expected to range between $5.9 billion and $6.1 billion. Adjusted EPS guidance was also updated to the high end of the original range of $2.40 to $2.50.

TAVR Growth Catalysts: The approval of the asymptomatic indication for the SAPIEN platform is expected to significantly expand the market and boost future growth. The management emphasized continued strong demand and a potential multiyear growth opportunity across the TAVR franchise supported by upcoming clinical evidence and changes in guidelines.